Enlivex Therapeutics Ltd (1BT F) stock market data APIs
€0.6762
0(0%)
as of May 8, 2026
Try our APIs with
free plan!
Enlivex Therapeutics Ltd Financial Data Overview
Price chart is built with
Anychart
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Prev. Close
0.6762
Open
0.6762
High
0.6762
Low
0.6762
52 wk Range
0.59-1.71
Market Cap
163 M
P/E Ratio
0.0311
Shares Outstanding
241 M
EPS
-0.17
Beta
1.489
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enlivex Therapeutics Ltd data using free add-ons & libraries
Get Enlivex Therapeutics Ltd Fundamental Data
Enlivex Therapeutics Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -14 668 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Enlivex Therapeutics Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: -0.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enlivex Therapeutics Ltd News
New
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
Enlivex Therapeutics Ltd Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/c...
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Enlivex Therapeutics Ltd Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy comp...
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
Enlivex Therapeutics Ltd Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceed...
Enlivex to Present at the 2023 Jefferies Healthcare Conference
Enlivex Therapeutics Ltd Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announce...
Get Enlivex Therapeutics Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
